To examine changes in treatment quality for Medicaid beneficiaries with opioid use disorder (OUD) from 2019 to 2023, highlighting the significance of this period in the context of the opioid crisis.
Key Findings:
MOUD treatment increased from 60.0% to 69.1% among Medicaid beneficiaries, indicating improved access.
180-day retention in MOUD treatment declined from 62.6% to 57.6%, raising concerns about treatment continuity.
States with low MOUD treatment rates in 2019 saw significant increases, with some states tripling their rates, reflecting successful policy interventions.
Policy changes have aimed to expand treatment access, including removing prior authorization and allowing telehealth for buprenorphine, but their impact on retention remains uncertain.
Interpretation:
The increase in MOUD treatment indicates progress in connecting Medicaid beneficiaries to effective care, but the decline in treatment retention highlights a critical need for improved care quality and continuity, with implications for future policy.
Limitations:
Lack of clear patterns in treatment continuity across states, which complicates the understanding of effective strategies.
Uncertainty regarding the impact of recent policy changes on treatment retention, necessitating further investigation.
Conclusion:
Future efforts should focus on enhancing retention in MOUD treatment through improved care coordination, clinician education, and financial incentives for treatment continuity, while also emphasizing the need for ongoing research to address these challenges.
Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.
